secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062036
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M
--------------------------------------------------------------------

- Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.
- Net loss $8.7M ($0.34 loss per share) vs $5.6M loss a year ago; operating expenses $21.0M.
- Q4 2023 revenue guidance $15.3M-$16.3M (64%-73% YoY growth); full-year $51M-$53M.
- Secured up to $90M debt facility; $40M drawn at closing; cash $60.1M as of Sept 30.
- Expect FDA approval of RECELL GO by May 30, 2024; targeting profitability in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/0000950170-23-062036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/rcel-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer